Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Oxygen debate: lower levels may be safer for COPD patients

NCT ID NCT04223050

Disease control Sponsor: Esbjerg Hospital - University Hospital of Southern Denmark Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study aimed to find the best oxygen level for people hospitalized with a sudden worsening of COPD. It compared giving enough oxygen to reach 88-92% saturation versus over 94%. The trial was stopped early after only 23 people took part, so the results are not strong enough to change practice.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Oxygen gas
What this could lead to
If successful, this could clarify the safest oxygen level for COPD patients during a flare-up, potentially reducing deaths.
What could go wrong
The trial was terminated early with only 23 participants, so results are very limited and may not be reliable. It is unclear if either oxygen target is truly better.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

23 people

The number who actually took part.

Started

Feb 2020

Finished

Aug 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * age 18 years or older * ability to give informed consent * previously diagnosed COPD (either confirmed diagnosis at prior hospital - contact or from their general practitioner or confirmed diagnosis by the treating physician in the emergency department (verified by use of relevant medication)) * admitted with acute exacerbation (acute and worsened shortness of breath) of COPD * requiring oxygen treatment Exclusion Criteria: * Instability at arrival requiring immediate lifesaving treatment, e.g. intubation or non-invasive ventilation, within the first 30 minutes * Expected total length of stay in hospital \< 12 hours * Planned transfer to another hospital within 12 hours * Unwilling to have repeated arterial blood gas analyses within the first 12 hours * Patients judged terminal by treating physician in the emergency department * Non-residents of the particular country * Expected impossible follow-up * Fertile women (\<50 years of age) with positive urine human gonadotropin (hCG) or plasma-hCG * Prior participation in the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic obstructive pulmonary disease exacerbation are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic obstructive pulmonary disease exacerbation COPD exacerbation

Contacts and locations

Locations

  • Holbæk Sygehus

    Holbæk, 4300, Denmark

  • Odense University Hospital

    Odense, 5000, Denmark

  • Sydvestjysk Sygehus

    Esbjerg, 6700, Denmark

  • Sygehus Lillebælt, Kolding

    Kolding, 6000, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.